M.D. Anderson Cancer Center: Inflammatory Breast Neoplasms trials

The registry lists 18 Inflammatory Breast Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 3 are open to participants now and 11 have results posted.

Phase 1 3Phase 2 14No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance MeasurementsRecruitingNCT07855627
• Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or MelanomaRecruitingNCT03941756Not applicable
• Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast CancerRecruitingNCT00477100
• Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestTerminatedNCT05243641Phase 1/2Results posted
• Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast CancerTerminatedNCT05041101Phase 1/2Results posted
• Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant ChemotherapyTerminatedNCT03872388Phase 2Results posted
• Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedNCT03101748Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to ChemotherapyActive, not recruitingNCT02971748Phase 2Results posted
• Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by SurgeryTerminatedNCT02658812Phase 2Results posted
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyActive, not recruitingNCT02411656Phase 2Results posted
• Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)TerminatedNCT02389764Phase 2Results posted
• TKI258 for Metastatic Inflammatory Breast Cancer PatientsCompletedNCT01262027Phase 2Results posted
• Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast CancerCompletedNCT01036087Phase 2Results posted
• Phase II Neoadjuvant in Inflammatory Breast CancerTerminatedNCT00756470Phase 2Results posted
• Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast CancerWithdrawnNCT05177796Phase 2
• Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerActive, not recruitingNCT03202316Phase 2
• Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast CancerActive, not recruitingNCT02876107Phase 2
• Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast CancerTerminatedNCT01755130Not applicable